The case for informative phase 2 trials in osteosarcoma
Lancet Oncol
.
2016 Aug;17(8):1022-1023.
doi: 10.1016/S1470-2045(16)30293-5.
Authors
Katherine A Janeway
1
,
Richard Gorlick
2
Affiliations
1
Dana-Farber Cancer Institute, Children's Hospital Boston, Pediatric Hematology Oncology, Boston, MA 02215, UAS. Electronic address: Katherine_janeway@dfci.harvard.edu.
2
The Children's Hospital of Montefiore, Bronx, NY, USA.
PMID:
27511145
DOI:
10.1016/S1470-2045(16)30293-5
No abstract available
Publication types
Comment
MeSH terms
Bone Neoplasms*
Humans
Osteosarcoma*